Dr. Jonathan S. Cross, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 724
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Miami, Lm Miller School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME0072217
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Regional Hospital Hollywood, FL
- Memorial Hospital West Pembroke Pines, FL
- Mount Sinai Medical Center of Florida, Inc Miami Beach, FL
- HCA Florida Aventura Hospital Aventura, FL
Medical groups
- Neuroscience Consultants LLP (115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 724
- Services billed
- 11,001
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 10,200 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 510 | 321 |
| Established patient office or other outpatient visit, 20-29 minutes | 320 | 243 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 219 | 132 |
| Annual depression screening, 5 to 15 minutes | 119 | 119 |
| New patient office or other outpatient visit, 45-59 minutes | 118 | 118 |
| Nerve conduction, 7-8 studies | 108 | 105 |
| New patient office or other outpatient visit, 30-44 minutes | 62 | 62 |
| Nerve conduction, 9-10 studies | 59 | 57 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 54 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Aventura, FL | 221 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Aventura, FL | 186 |
| Rytary (carbidopa/levodopa) Other prescribers in Aventura, FL | 133 |
| Memantine Hcl Other prescribers in Aventura, FL | 118 |
| Quetiapine Fumarate Other prescribers in Aventura, FL | 73 |
| Duloxetine Hcl Other prescribers in Aventura, FL | 69 |
| Gabapentin Other prescribers in Aventura, FL | 68 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 64 |
| Propranolol Hcl Er (propranolol hcl) Other prescribers in Aventura, FL | 64 |
| Pregabalin Other prescribers in Aventura, FL | 63 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 219 payments worth $29,460 in total to this clinician.
| Eisai Inc. | $8,423 |
|---|---|
| AbbVie Inc. | $6,535 |
| Argenx US, Inc. | $5,698 |
| Biogen, Inc. | $2,201 |
| Abbott Laboratories | $1,872 |
| Pfizer Inc. | $1,740 |
| Teva Pharmaceuticals USA, Inc. | $392 |
| EMD Serono, Inc. | $357 |
| Consulting Fee | $18,348 |
|---|---|
| Food and Beverage | $5,552 |
| Travel and Lodging | $5,475 |
| Education | $84.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Oct 1, 2025 | Consulting Fee Leqembi · Neurology | $5,720 |
| AbbVie Inc. Aug 20, 2025 | Consulting Fee | $4,550 |
| Argenx US, Inc. Dec 5, 2025 | Consulting Fee VYVGART HYTRULO · Neurology | $4,500 |
| Biogen, Inc. Jan 28, 2025 | Consulting Fee | $2,018 |
| Eisai Inc. May 1, 2025 | Consulting Fee Leqembi · Neurology | $1,560 |
| Abbott Laboratories Apr 28, 2025 | Travel and Lodging INFINITY · Structural Heart · travel to Austin, TX · in-kind | $879 |
| Pfizer Inc. May 23, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Chicago, IL · in-kind | $809 |
| Abbott Laboratories Apr 28, 2025 | Travel and Lodging INFINITY · Structural Heart · travel to Austin, TX · in-kind | $680 |
| Argenx US, Inc. Nov 8, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Atlanta, GA | $677 |
| Eisai Inc. Oct 1, 2025 | Travel and Lodging Leqembi · Neurology · travel to Toronto, Canada | $619 |
All 23 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Dec 5, 2025 | Consulting Fee VYVGART HYTRULO · Neurology | $4,500 |
| Argenx US, Inc. Nov 9, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Atlanta, GA | $53.06 |
| Argenx US, Inc. Nov 8, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Atlanta, GA | $677 |
| Argenx US, Inc. Nov 8, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Atlanta, GA | $70.00 |
| Argenx US, Inc. Nov 7, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Atlanta, GA | $37.11 |
| Janssen Biotech, Inc. Nov 6, 2025 | Education in-kind | $84.99 |
| Eisai Inc. Oct 1, 2025 | Consulting Fee Leqembi · Neurology | $5,720 |
| Eisai Inc. Oct 1, 2025 | Travel and Lodging Leqembi · Neurology · travel to Toronto, Canada | $619 |
| Eisai Inc. Oct 1, 2025 | Travel and Lodging Leqembi · Neurology · travel to Toronto, Canada | $66.45 |
| AbbVie Inc. Aug 20, 2025 | Consulting Fee | $4,550 |
| AbbVie Inc. Aug 3, 2025 | Travel and Lodging travel to DENVER, CO · in-kind | $518 |
| AbbVie Inc. Aug 2, 2025 | Travel and Lodging travel to DENVER, CO · in-kind | $311 |
| AbbVie Inc. Aug 2, 2025 | Travel and Lodging travel to DENVER, CO · in-kind | $311 |
| Abbott Laboratories May 29, 2025 | Travel and Lodging INFINITY · Structural Heart · travel to El Segundo, CA · in-kind | $40.42 |
| Pfizer Inc. May 23, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Chicago, IL · in-kind | $809 |
| Pfizer Inc. May 23, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Chicago, IL · in-kind | $257 |
| Eisai Inc. May 1, 2025 | Consulting Fee Leqembi · Neurology | $1,560 |
| Abbott Laboratories Apr 28, 2025 | Travel and Lodging INFINITY · Structural Heart · travel to Austin, TX · in-kind | $879 |
| Abbott Laboratories Apr 28, 2025 | Travel and Lodging INFINITY · Structural Heart · travel to Austin, TX · in-kind | $680 |
| Abbott Laboratories Apr 28, 2025 | Travel and Lodging PROCLAIM · Structural Heart · travel to El Segundo, CA · in-kind | $121 |
| Abbott Laboratories Apr 28, 2025 | Travel and Lodging INFINITY · Structural Heart · travel to Austin, TX · in-kind | $9.02 |
| Biogen, Inc. Jan 28, 2025 | Consulting Fee | $2,018 |
| Biogen, Inc. Jan 28, 2025 | Travel and Lodging travel to Fort Lauderdale, FL | $17.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $589,120 in research payments for these studies, mostly to the institutions running them.
- A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company · Active, not recruiting · NCT05738486 - A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT05026866 - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047457 - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047444 - A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy
Vertex Pharmaceuticals Incorporated - A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.